LEXINGTON, Mass.--(BUSINESS WIRE)--Aug. 16, 2006--Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) today announced that the New England Journal of Medicine (NEJM) has published results from the company’s landmark Phase 3 study of CUBICIN(R) (daptomycin for injection) at 6 mg/kg as monotherapy vs. dual therapy standard of care for the treatment of patients with Staphylococcus aureus (S. aureus) blood stream infections (bacteremia) and infective endocarditis (infection of the heart valves). The study results, which are featured in the August 17, 2006 issue of the NEJM, show that CUBICIN at 6 mg/kg intravenously once daily was as effective as standard-of-care comparator for the treatment of S. aureus bacteremia including right-sided endocarditis. On May 26th, the FDA approved a supplemental New Drug Application (sNDA) to expand the indication for CUBICIN at 6 mg/kg once daily to treat patients with S. aureus blood stream infections including right-sided endocarditis.
